Sign In
Buy TKPHF
$30.19
-2.30 (-7.07%)
At Close: Jun 22, 2026
Takeda Pharmaceutical Company Earnings Calls
Mar 31, 2026
-$0.0980 (35.21%)
| Release date | May 13, 2026 |
| EPS estimate | -$0.151 |
| EPS actual | -$0.0980 |
| EPS Surprise | 35.21% |
| Revenue estimate | 7.07B |
| Revenue actual | 6.893B |
| Revenue Surprise | -2.50% |
Dec 31, 2025
$0.420 (52.38%)
| Release date | Jan 29, 2026 |
| EPS estimate | $0.275 |
| EPS actual | $0.420 |
| EPS Surprise | 52.38% |
| Revenue estimate | 7.605B |
| Revenue actual | 7.604B |
| Revenue Surprise | -0.0046% |
Sep 30, 2025
-$0.0499 (-135.56%)
| Release date | Oct 30, 2025 |
| EPS estimate | $0.140 |
| EPS actual | -$0.0499 |
| EPS Surprise | -135.56% |
| Revenue estimate | 7.48B |
| Revenue actual | 7.417B |
| Revenue Surprise | -0.85% |
Jun 30, 2025
(Upcoming)
| Release date | Jul 30, 2026 |
| EPS estimate | $0.326 |
| EPS actual | - |
| Revenue estimate | 7.151B |
| Revenue actual | - |
| Expected change | +/- 2.30% |
Last 4 Quarters for Takeda Pharmaceutical Company
Below you can see how TKPHF performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Jun 30, 2025
(Upcoming)
| Release date | Jul 30, 2026 |
| Price on release | - |
| EPS estimate | $0.326 |
| EPS actual | - |
| Date | Price |
|---|---|
| Jun 15, 2026 | $32.48 |
| Jun 16, 2026 | $32.48 |
| Jun 17, 2026 | $32.48 |
| Jun 18, 2026 | $32.48 |
| Jun 22, 2026 | $30.19 |
Sep 30, 2025
Missed
| Release date | Oct 30, 2025 |
| Price on release | $27.73 |
| EPS estimate | $0.140 |
| EPS actual | -$0.0499 |
| EPS surprise | -135.56% |
| Date | Price |
|---|---|
| Oct 24, 2025 | $28.20 |
| Oct 27, 2025 | $29.05 |
| Oct 28, 2025 | $29.05 |
| Oct 29, 2025 | $29.05 |
| Oct 30, 2025 | $27.73 |
| Oct 31, 2025 | $27.73 |
| Nov 03, 2025 | $26.44 |
| Nov 04, 2025 | $26.44 |
| Nov 05, 2025 | $26.44 |
| 4 days before | -1.67% |
| 4 days after | -4.64% |
| On release day | 0% |
| Change in period | -6.23% |
Dec 31, 2025
Beat
| Release date | Jan 29, 2026 |
| Price on release | $31.12 |
| EPS estimate | $0.275 |
| EPS actual | $0.420 |
| EPS surprise | 52.38% |
| Date | Price |
|---|---|
| Jan 23, 2026 | $31.12 |
| Jan 26, 2026 | $31.12 |
| Jan 27, 2026 | $31.12 |
| Jan 28, 2026 | $31.12 |
| Jan 29, 2026 | $31.12 |
| Jan 30, 2026 | $31.12 |
| Feb 02, 2026 | $31.12 |
| Feb 03, 2026 | $31.12 |
| Feb 04, 2026 | $35.08 |
| 4 days before | 0% |
| 4 days after | 12.71% |
| On release day | 0% |
| Change in period | 12.71% |
Mar 31, 2026
Beat
| Release date | May 13, 2026 |
| Price on release | $32.68 |
| EPS estimate | -$0.151 |
| EPS actual | -$0.0980 |
| EPS surprise | 35.21% |
| Date | Price |
|---|---|
| May 07, 2026 | $32.25 |
| May 08, 2026 | $32.25 |
| May 11, 2026 | $32.68 |
| May 12, 2026 | $32.68 |
| May 13, 2026 | $32.68 |
| May 14, 2026 | $32.68 |
| May 15, 2026 | $32.68 |
| May 18, 2026 | $32.26 |
| May 19, 2026 | $32.26 |
| 4 days before | 1.34% |
| 4 days after | -1.30% |
| On release day | 0% |
| Change in period | 0.0298% |
Takeda Pharmaceutical Company Earnings History
Earnings Calendar
FAQ
When is the earnings report for TKPHF?
Takeda Pharmaceutical Company Limited (TKPHF) has scheduled its earnings report for Jul 30, 2026 after the markets close.
What is the TKPHF price-to-earnings (P/E) ratio?
TKPHF P/E ratio as of Jun 22, 2026 (TTM) is 40.79.
What is the TKPHF EPS forecast?
The forecasted EPS (Earnings Per Share) for Takeda Pharmaceutical Company Limited (TKPHF) for the first fiscal quarter 2025 is $0.326.
What are Takeda Pharmaceutical Company Limited's retained earnings?
On its balance sheet, Takeda Pharmaceutical Company Limited reported retained earnings of $6.89 billion for the latest quarter ending Mar 31, 2026.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
